EC grants orphan drug designation to ALXN1007 for treatment of patients with GVHD
Alexion announced the EC has granted orphan drug designation to ALXN1007, a novel anti-inflammatory monoclonal antibody targeting complement protein C5a, for treatment of graft-versus-host disease. Alexion is currently investigating ALXN1007 in patients with acute GI-GVHD. August 29, 2016